BioCryst Pharmaceuticals saw a 6.7% quarter-over-quarter revenue increase for its drug Orladeyo, reaching $158.2 million in Q2. The company also reduced its royalty financing obligations from $465.7 million at the end of 2025 to $426.8 million by June. Additionally, BioCryst's acquisition of navenibart, a potential treatment for hereditary angioedema (HAE), is viewed as a strategic move that supports a positive risk/reward profile, with analysts projecting a 149% upside in stock price. This positions BioCryst as an attractive investment opportunity in the HAE market following recent industry activity like Chiesi's acquisition of KalVista.
Argus Research increased its price target for NetApp to $225, citing a 13.5% potential upside from the current price of $198.18. NetApp reported strong fiscal Q1 2027 results with revenues up 29.9% to over $2 billion and non-GAAP EPS rising 66.5% to ...
New Jersey American Water received approval for rate increases that will add $68 million annually to its revenue. This funding supports over $1.4 billion in critical infrastructure upgrades, including replacing aging water mains and improving treatme...
MoneyHero Limited reported Q3 2026 earnings with an EPS of -$0.03 and revenue of $15.75 million, missing analyst estimates. The company is shifting strategy to offer more cash rewards to attract users, which has lowered immediate revenue and resulted...
Itaconix plc announced record revenues for the first half of 2026, marking their fourth consecutive period of revenue growth. The company achieved breakeven EBITDA profitability for the first half while continuing to invest in new products and operat...
Binance's bitcoin reserves have risen to over 693,000 BTC, the highest in two years and about 30% of all major exchange reserves. This increase of roughly 77,000 BTC since April raises potential sell-side pressure as Bitcoin faces a strong resistance...
